News

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

Primer Capital has been awarded the Best Biotech VC Fund – Europe by Wealth & Money Management Awards 2019.

The founder of Data MATRIX (Primer Capital's portfolio project) entered the ranking of the top 20 most successful MedTech entrepreneurs according to RusBase. 

Anton Lavrentev, head of the legal department at Primer Capital, in his interview for VC.ru talked about ethical components which are essential for investors to consider before taking on new target. 

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech. 

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.